argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-07-21 08:12 |
argenx to Report Half Year 2022 Financial Results and Second Quarter Business U…
|
English | 22.9 KB | ||
| 2022-06-24 08:05 |
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adu…
|
English | 53.3 KB | ||
| 2022-06-01 09:03 |
argenx to Present at Upcoming Investor Conferences
|
English | 21.8 KB | ||
| 2022-05-31 09:35 |
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Gener…
|
English | 42.3 KB | ||
| 2022-05-19 14:11 |
argenx Announces Publication of Translational Data of Efgartigimod in Autoimmun…
|
English | 54.8 KB | ||
| 2022-05-11 08:39 |
argenx announces results of Annual General Meeting of Shareholders
|
English | 26.4 KB | ||
| 2022-05-05 08:35 |
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartig…
|
English | 145.8 KB | ||
| 2022-05-05 08:34 |
argenx Reports First Quarter 2022 Financial Results and Provides Business Update
|
English | 125.4 KB | ||
| 2022-05-04 08:18 |
argenx to Present at BofA Securities 2022 Healthcare Conference
|
English | 17.4 KB | ||
| 2022-04-28 08:50 |
argenx to Report First Quarter 2022 Financial Results and Business Update on Ma…
|
English | 19.8 KB | ||
| 2022-04-05 08:40 |
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluati…
|
English | 134.9 KB | ||
| 2022-04-01 07:48 |
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 A…
|
English | 564.5 KB | ||
| 2022-03-30 08:38 |
argenx announces full exercise of underwriters’ option to purchase additional A…
|
English | 52.6 KB | ||
| 2022-03-30 08:31 |
argenx announces Annual General Meeting of Shareholders on May 10, 2022
|
English | 29.3 KB | ||
| 2022-03-29 08:30 |
argenx announces closing of global offering
|
English | 46.8 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
